

Principle of Hybrid Capture 2 (HC2) Technology Print Bookmark Share more.. Learn about HC2, the platform for the digene HPV Test Hybrid Capture 2 (HC2) technology serves as the platform for QIAGEN’s nucleic acid hybridization assay for detection of human papillomavirus (HPV). Rapid, standardized testing for your lab Main Image Navi The diagnostic method of the digene HC2 High-Risk HPV DNA Test and the digene HC2 HPV DNA Test (which are collectively called the digene HPV Test) allows rapid, standardized testing of genetic material of the infectious agents in virtually any laboratory setting. It employs specific RNA probes, hybridization, antibody capture, and signal amplification that utilizes qualitative chemiluminescent detection. Clinical sensitivity is critical How HC2 technology works The digene HPV Test, using Hybrid Capture 2 technology, provides an accurate, cost-effective, user-friendly method by achieving reliable and reproducible detection. Benefits of HC2: Full-length probe for reliable senstivity and specificity with no risk due to deletions Unmatched cervical intraepithelial neoplasia (CIN) 2+ sensitivity Same day results in a microplate test format High-throughput automation for handling increasing test volumes Minimal specimen preparation required for fast and efficient sample processing Signal amplification method with reduced cross-contamination risk Extensive, clinical validation data available Back to top Clinical sensitivity is critical For routine HPV diagnostics and clinical decision making, clinical sensitivity is critical. The HC2 technology fulfills this requirement better than any other method as outlined in multiple clinical validation studies. Cervical cancer screening methods require HPV detection correlating to disease and not to the sheer presence of the virus, since 90% of infections is cleared by itself without consequences. HC2 technology measures sensitivity versus defined clinical endpoints (CIN 3+/SCC) and ensures reporting of positive results only when risk of disease progression exists. QIAGEN’s digene HPV Test has an excellent clinical sensitivity of up to 100% in primary adjunctive screening when combined with a Pap smear test [Mayrand, M.H., et al. (2007) N. Engl. J. Med. 357(16), 1579.]. Clinically validated cutoff of 5000 copies/ml Proven in extensive multiple trials Ensures high negative predictive value Back to top How Hybrid Capture 2 technology works The HC2 System is a signal-amplification assay that uses a technique combining antibody capture and chemiluminescent signal detection. Contact QIAGEN Global contacts Technical Service Customer Care

Principle of Hybrid Capture 2 (HC2) Technology

Learn about HC2, the platform for the digene HPV Test

Hybrid Capture 2 (HC2) technology serves as the platform for QIAGEN’s nucleic acid hybridization assay for detection of human papillomavirus (HPV).

The diagnostic method of the digene HC2 High-Risk HPV DNA Test and the digene HC2 HPV DNA Test (which are collectively called the digene HPV Test) allows rapid, standardized testing of genetic material of the infectious agents in virtually any laboratory setting. It employs specific RNA probes, hybridization, antibody capture, and signal amplification that utilizes qualitative chemiluminescent detection.

Clinical sensitivity is critical
How HC2 technology works

The digene HPV Test, using Hybrid Capture 2 technology, provides an accurate, cost-effective, user-friendly method by achieving reliable and reproducible detection.

Benefits of HC2:

Full-length probe for reliable senstivity and specificity with no risk due to deletions
Unmatched cervical intraepithelial neoplasia (CIN) 2+ sensitivity
Same day results in a microplate test format
High-throughput automation for handling increasing test volumes
Minimal specimen preparation required for fast and efficient sample processing
Signal amplification method with reduced cross-contamination risk
Extensive, clinical validation data available

Back to top Clinical sensitivity is critical

For routine HPV diagnostics and clinical decision making, clinical sensitivity is critical. The HC2 technology fulfills this requirement better than any other method as outlined in multiple clinical validation studies. Cervical cancer screening methods require HPV detection correlating to disease and not to the sheer presence of the virus, since 90% of infections is cleared by itself without consequences.
HC2 technology measures sensitivity versus defined clinical endpoints (CIN 3+/SCC) and ensures reporting of positive results only when risk of disease progression exists. QIAGEN’s digene HPV Test has an excellent clinical sensitivity of up to 100% in primary adjunctive screening when combined with a Pap smear test [Mayrand, M.H., et al. (2007) N. Engl. J. Med. 357(16), 1579.].

Clinically validated cutoff of 5000 copies/ml
Proven in extensive multiple trials
Ensures high negative predictive value

Back to top How Hybrid Capture 2 technology works

The HC2 System is a signal-amplification assay that uses a technique combining antibody capture and chemiluminescent signal detection.